<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CAT</journal-id>
<journal-id journal-id-type="hwp">spcat</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Appl Thromb Hemost</journal-id>
<journal-title>Clinical and Applied Thrombosis/Hemostasis</journal-title>
<issn pub-type="ppub">1076-0296</issn>
<issn pub-type="epub">1938-2723</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1076029611424576</article-id>
<article-id pub-id-type="publisher-id">10.1177_1076029611424576</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the Editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fibrinogen, Hematocrit, and Platelets in Mild Kidney Dysfunction and the Role of Uric Acid: An Italian Male Population Study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Katsiki</surname>
<given-names>Niki</given-names>
</name>
<degrees>MD, MSc, FRSPH</degrees>
<xref ref-type="aff" rid="aff1-1076029611424576">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Athyros</surname>
<given-names>Vasilios G.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-1076029611424576">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karagiannis</surname>
<given-names>Asterios</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-1076029611424576">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Mikhailidis</surname>
<given-names>Dimitri P.</given-names>
</name>
<degrees>BSc, MSc, MD, FRSPH, FCP, FFPM, FRCP, FRCPath</degrees>
<xref ref-type="aff" rid="aff1-1076029611424576">1</xref>
<xref ref-type="corresp" rid="corresp1-1076029611424576"/>
</contrib>
</contrib-group>
<aff id="aff1-1076029611424576"><label>1</label>Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London NW3 2QG, UK</aff>
<aff id="aff2-1076029611424576"><label>2</label>Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece</aff>
<author-notes>
<corresp id="corresp1-1076029611424576">Dimitri P. Mikhailidis, Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK. Email:<email>mikhailidis@aol.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>113</fpage>
<lpage>114</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January/Febraury 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Indeed there is a close relationship between estimated glomerular filtration rate (eGFR) and serum uric acid (SUA) levels.<sup><xref ref-type="bibr" rid="bibr1-1076029611424576">1</xref></sup> This may explain the concomitant improvement in SUA levels and eGFR observed in patients with coronary heart disease (CHD) or peripheral arterial disease after prescribing a statin.<sup><xref ref-type="bibr" rid="bibr2-1076029611424576">2</xref><xref ref-type="bibr" rid="bibr3-1076029611424576"/>–<xref ref-type="bibr" rid="bibr4-1076029611424576">4</xref></sup> Of additional interest, in the CHD studies,<sup><xref ref-type="bibr" rid="bibr2-1076029611424576">2</xref>,<xref ref-type="bibr" rid="bibr3-1076029611424576">3</xref></sup> SUA was an independent predictor of CHD recurrent events.</p>
<p>We reviewed the evidence showing an association between SUA levels and abnormal liver function tests (LFTs) in patients with nonalcoholic fatty liver disease (NAFLD).<sup><xref ref-type="bibr" rid="bibr5-1076029611424576">5</xref></sup> We also showed that NAFLD was associated with a greater risk of vascular events in patients with CHD.<sup><xref ref-type="bibr" rid="bibr6-1076029611424576">6</xref></sup> Furthermore, in this study,<sup><xref ref-type="bibr" rid="bibr6-1076029611424576">6</xref></sup> patients with NAFLD on a statin benefited more from lipid-lowering treatment than those without NAFLD in terms of a decrease in vascular events. In this context, does the study by Corrêa Leite<sup><xref ref-type="bibr" rid="bibr1-1076029611424576">1</xref></sup> discusses about LFTs If yes, we would be interested to know whether there are any significant correlations between LFTs and SUA levels.<sup><xref ref-type="bibr" rid="bibr5-1076029611424576">5</xref></sup>
</p>
<p>Hyperuricemia seems to be more frequent in patients with metabolic syndrome, a condition that is associated with increased risk of vascular events.<sup><xref ref-type="bibr" rid="bibr7-1076029611424576">7</xref></sup> It follows that we would be interested to know whether the population described by Corrêa Leite<sup><xref ref-type="bibr" rid="bibr1-1076029611424576">1</xref></sup> could be reanalyzed as those with and without metabolic syndrome.</p>
<p>Several drugs can influence SUA levels.<sup><xref ref-type="bibr" rid="bibr8-1076029611424576">8</xref></sup> These associations complicate the definition of the contribution of SUA to the risk of vascular events.</p>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-1076029611424576">
<p>We read with great interest the article by Corrêa Leite<sup><xref ref-type="bibr" rid="bibr1-1076029611424576">1</xref></sup>. A few comments may be of interest.</p>
</fn>
<fn fn-type="conflict" id="fn2-1076029611424576">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1076029611424576">
<p>The authors received no financial support for the research, authorship, and/or publication of this article..</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1076029611424576">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corrêa Leite</surname>
<given-names>ML.</given-names>
</name>
</person-group> <article-title>Fibrinogen, hematocrit, platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study</article-title>. <source>Clin Appl Thromb Hemost</source>. <year>2011</year>;<volume>17</volume>(<issue>1</issue>):<fpage>58</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr2-1076029611424576">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papageorgiou</surname>
<given-names>AA</given-names>
</name>
<etal/>
</person-group>. <article-title>GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study</article-title>. <source>Am J Kidney Dis</source>. <year>2004</year>;<volume>43</volume>(<issue>4</issue>):<fpage>589</fpage>–<lpage>599</lpage>.</citation>
</ref>
<ref id="bibr3-1076029611424576">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Liberopoulos</surname>
<given-names>EN</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study</article-title>. <source>Nephrol Dial Transplant</source>. <year>2007</year>;<volume>22</volume>(<issue>1</issue>):<fpage>118</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr4-1076029611424576">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youssef</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Seifalian</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Myint</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease</article-title>. <source>Angiology</source>. <year>2004</year>;<volume>55</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr5-1076029611424576">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katsiki</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP.</given-names>
</name>
</person-group> <article-title>Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): a relationship with implications for vascular risk? [published online ahead of print March 10 2011]</article-title>. <source>Curr Vasc Pharmacol</source>. <year>2011</year>.</citation>
</ref>
<ref id="bibr6-1076029611424576">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Tziomalos</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gossios</surname>
<given-names>TD</given-names>
</name>
<etal/>
</person-group>. <article-title>GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>(<issue>9756</issue>):<fpage>1916</fpage>–<lpage>1922</lpage>.</citation>
</ref>
<ref id="bibr7-1076029611424576">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsouli</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Liberopoulos</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>MS.</given-names>
</name>
</person-group> <article-title>Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?</article-title>. <source>Metabolism</source>. <year>2006</year>;<volume>55</volume>(<issue>10</issue>):<fpage>1293</fpage>–<lpage>1301</lpage>.</citation>
</ref>
<ref id="bibr8-1076029611424576">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalopoulou</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Tzovaras</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Elisaf</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia</article-title>. <source>Curr Pharm Des</source>. <year>2005</year>;<volume>11</volume>(<issue>32</issue>):<fpage>4161</fpage>–<lpage>4175</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>